• Dermot P Maher, Chi Heem Wong, Kien Wei Siah, and Andrew W Lo.
• Johns Hopkins University School of Medicine, Baltimore, Maryland.
• Anesthesiology. 2022 Aug 1; 137 (2): 243-251.

BackgroundThe authors estimate the probability of successful development and duration of clinical trials for medications to treat neuropathic and nociceptive pain. The authors also consider the effect of the perceived abuse potential of the medication on these variables.MethodsThis study uses the Citeline database to compute the probabilities of success, duration, and survivorship of pain medication development programs between January 1, 2000, and June 30, 2020, conditioned on the phase, type of pain (nociceptive vs. neuropathic), and the abuse potential of the medication.ResultsThe overall probability of successful development of all pain medications from phase 1 to approval is 10.4% (standard error, 1.5%). Medications to treat nociceptive and neuropathic pain have a probability of successful development of 13.3% (standard error, 2.3%) and 7.1% (standard error, 1.9%), respectively. The probability of successful development of medications with high abuse potential and low abuse potential are 27.8% (standard error, 4.6%) and 4.7% (standard error, 1.2%), respectively. The most common period for attrition is between phase 3 and approval.ConclusionsThe authors' data suggest that the unique attributes of pain medications, such as their abuse potential and intended pathology, can influence the probability of successful development and duration of development.Editor’s PerspectiveCopyright © 2022, the American Society of Anesthesiologists. All Rights Reserved.

12 keywords...

hide…